W
WAVEMAN · COMPANY
EOLS · Evolus, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

EOLS

Evolus, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001570562
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$797.2K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
90
13F, latest reported quarter
REVENUE GROWTH
+11.6%
XBRL, annual
NET MARGIN
-17.4%
CONVERSIONS · 180D
2
codes C/M, not in net · $0 priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$797.2K over 180 days
below 58% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
90 funds added or opened last quarter
more than 61% of Pharma & Biotech
REVENUE
+11.6% year over year
more than 62% of Pharma & Biotech
MARGIN
-17.4% net margin
more than 51% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
8.4% of shares outstanding short · 8.7 days to cover · settled 2026-07-31
more than 70% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
90 funds added or opened positions in the latest 13F quarter, of 159 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +20.8%
+20.8%12M
-47%-25%-2%+21%2025-092025-102025-122026-032026-052026-072026-09 2026-09-02 · MOATAZEDI DAVID sold $950.0K2026-03-17 · MOATAZEDI DAVID sold $570.8K2026-03-17 · Avelar Rui sold $146.7K2025-12-22 · MOATAZEDI DAVID sold $75.4K2026-03-20 · MOATAZEDI DAVID sold $64.9K2025-12-22 · Avelar Rui sold $16.2K2026-03-20 · Avelar Rui sold $14.8K2026-09-02 · DAVID MOATAZEDI filed to sell $950.0K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $797.2K sold by insiders over 180 days, 90 funds added last quarter, $950.0K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Evolus, Inc. insiders sold a net $797.2K of stock across 111 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
MOATAZEDI DAVID
See Remarks
SELL
2026-09-02
105,108.0
$950.0K
Avelar Rui
See Remarks
SELL
2026-03-20
3,119.0
$14.8K
MOATAZEDI DAVID
See Remarks
SELL
2026-03-20
13,669.0
$64.9K
MOATAZEDI DAVID
See Remarks
SELL
2026-03-17
116,720.0
$570.8K
Avelar Rui
See Remarks
SELL
2026-03-17
29,996.0
$146.7K
111 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 106 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Nantahala Capital Management, LLC
11,204,042.0 sh
$77.8M
BlackRock, Inc.
4,840,828.0 sh
$33.6M
Stonepine Capital Management, LLC
3,180,324.0 sh
$22.1M
BRAIDWELL LP
3,155,209.0 sh
$21.9M
Frazier Life Sciences Management, L.P.
2,630,665.0 sh
$18.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
DAVID MOATAZEDI
FILED 2026-09-02
$950.0K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$165.6K POSITION · AS OF 2026-03-31
0.8%
Clearwater Select Equity Fund
$475.5K POSITION · AS OF 2026-03-31
0.1%
iShares U.S. Pharmaceuticals ETF
$744.6K POSITION · AS OF 2026-03-31
0.1%
iShares Micro-Cap ETF
$580.5K POSITION · AS OF 2026-03-31
0.0%
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF
$377.1K POSITION · AS OF 2026-02-28
0.0%
1290 VT Micro Cap Portfolio
$42.2K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 2 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 2
0 ACTIVE
1
Not applicable
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Mr. Moatazedi
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$6.4M
-$746.5K
$2.0M
+2%
+20%
2024
$7.0M
$4.8M
$2.1M
+70%
-9%
2023
$11.2M
$13.6M
$2.7M
+62%
-8%
2022
$3.6M
$5.8M
$1.5M
+15%
-10%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$297.2M$266.3M$202.1M$148.6M
GROSS PROFIT$197.1M$182.3M$137.6M$89.8M
OPERATING INCOME$-32.7M$-34.4M$-49.2M$-65.3M
NET INCOME$-51.6M$-50.4M$-61.7M$-74.4M
EPS (DILUTED)-0.80-0.81-1.08-1.33
OPERATING CASH FLOW$-42.3M$-18.0M$-34.0M$-84.9M
CASH$53.8M$87.0M$62.8M$53.9M
LONG-TERM DEBT$146.1M$121.5M$120.4M$71.9M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →